Abstract
IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Molecular mechanisms regulating expression of IL-6R are not well understood and current therapies are based on monoclonal antibody to target IL-6 signaling. Small molecule inhibitors targeting IL-6 signaling are highly desirable. Metformin specifically decreased IL-6R expression which is mediated via AMPK, mTOR, and miR34a. This is a novel finding and adds to existing therapies targeting IL-6 signaling.
Original language | English (US) |
---|---|
Pages (from-to) | 2695-2709 |
Number of pages | 15 |
Journal | Leukemia |
Volume | 33 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2019 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research